{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:14Z","timestamp":1793320634830,"version":"4.5.0"},"reference-count":209,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and remains a major therapeutic challenge. In recent years, immune checkpoint inhibitors (ICIs), represented by PD-1\/PD-L1 and CTLA-4 inhibitors, have revolutionized the field of HCC treatment and become the cornerstone of standard immunotherapy regimens, drastically altering the treatment landscape for advanced and unresectable HCC. However, primary and\/or acquired drug resistance remains the leading cause of treatment failure, severely limiting the long-term clinical benefits of immunotherapy for HCC patients. This review aims to systematically summarize current research on immunotherapy for HCC, with a focus on drug resistance mechanisms across multiple dimensions: immunosuppressive tumor microenvironment, intrinsic tumor cell factors, and systemic and environmental influences. Potential strategies to overcome resistance are discussed, such as rational combination therapy with antiangiogenic or targeted agents, novel immune targets, nanotechnology-enabled precise delivery, and tumor organoid models for personalized treatment. Future advancements should focus on precision multimodal combinations, innovative therapeutic platforms, and individualized strategies guided by multi-omics and AI, aiming to overcome efficacy bottlenecks and improve patient survival.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1808109","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:41:36Z","timestamp":1776231696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug resistance mechanisms of immunotherapy and translational strategies for reversing resistance for hepatocellular carcinoma: from bench to bedside"],"prefix":"10.3389","volume":"17","author":[{"given":"Chenfang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Second Hospital of Jilin University, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global Cancer Statistics 2022: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA: A Cancer J For Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000541622","article-title":"Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 edition)","volume":"14","author":"Yang","year":"2025","journal-title":"Liver Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.20517\/ais.2024.09","article-title":"Application of artificial intelligence to hepatobiliary cancer clinical outcomes research","volume":"4","author":"Yutaka","year":"2024","journal-title":"Artif Intell Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpt.2025.04.004","article-title":"Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies","volume":"4","author":"Sutanto","year":"2026","journal-title":"Cancer Pathog Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: Asco guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2902052","article-title":"Drug resistance in hepatocellular carcinoma: Theoretical basis and therapeutic aspects","volume":"29","author":"Lei","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.20517\/2394-4722.2023.175","article-title":"Research advances in immunotherapy combined with DNA damage response inhibitors for liver cancer therapy","volume":"10","author":"Chen","year":"2024","journal-title":"J Cancer Metastasis Treat"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000237","article-title":"Mechanisms of drug resistance in Hcc","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17233870","article-title":"Current immunotherapy strategies and emerging biomarkers for the treatment of hepatocellular carcinoma","volume":"17","author":"Kapelanski-Lamoureux","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011091","article-title":"Hepatocellular carcinoma immunotherapy: Predictors of response, issues, and challenges","volume":"25","author":"Rizzo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020236","article-title":"Next-generation immunotherapy for hepatocellular carcinoma: Mechanisms of resistance and novel treatment approaches","volume":"17","author":"Eghbali","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.117394","article-title":"Immunotherapy resistance in Masld-related hepatocellular carcinoma: Special immune microenvironment and gut microbiota","volume":"21","author":"Jin","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2025.2568904","article-title":"Immunology, immunotherapy, and the tumor microenvironment in hepatocellular carcinoma: A comprehensive review","volume":"21","author":"Akabane","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01982-8","article-title":"The role of Pd-1\/Pd-L1 axis in liver diseases","volume":"26","author":"Zeng","year":"2025","journal-title":"Clin Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790963","article-title":"Emerging role of Pd-1\/Pd-L1 inhibitors in chronic liver diseases","volume":"12","author":"Singh","year":"2021","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (checkmate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (Checkmate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (checkmate 9dw): An open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (keynote-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/jco.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: A randomized, double-blind, phase iii trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00620","article-title":"Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase iii trial","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00808","article-title":"Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000527175","article-title":"Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (rationale-208): A multicenter, non-randomized, open-label, phase 2 trial","volume":"12","author":"Ren","year":"2023","journal-title":"Liver Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000537966","article-title":"Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in rationale-301 study","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (ibi305) versus sorafenib in unresectable hepatocellular carcinoma (orient-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: A randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (Rescue): A nonrandomized, open-label, phase Ii trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: A single-arm, open label, phase ii clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/s1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (Imbrave150): An open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01462","article-title":"Patient-reported outcomes from the phase iii himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The Checkmate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/jco.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase i\/ii study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.07.017","article-title":"Outcomes in the Asian subgroup of the phase iii randomised himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"82","author":"Lau","year":"2025","journal-title":"J Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31601-x","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (Keynote-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: Updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02437-1","article-title":"Checkpoint inhibitors and anti-angiogenic agents: A winning combination","volume":"129","author":"Brest","year":"2023","journal-title":"Br J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798","article-title":"Pd-1\/Pd-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042220-021121","article-title":"Hepatocellular carcinoma immunotherapy","volume":"73","author":"Sperandio","year":"2022","journal-title":"Annu Rev Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbe1603028","article-title":"Biotechnological advances utilizing aptamers and peptides refining Pd-L1 targeting","volume":"16","author":"Timilsina","year":"2024","journal-title":"Front Biosci (Elite Ed)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of Pd-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in Pd-L1\/Pd-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150735","article-title":"Vegfr2 activity on myeloid cells mediates immune suppression in the tumor microenvironment","volume":"6","author":"Zhang","year":"2021","journal-title":"JCI Insight"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--Ctla-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459","article-title":"Cd28 and Ctla-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003060","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"137","author":"Wang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"B62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"Car-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/med4.37","article-title":"Oncogenic viral antigens for engineered T cell immunotherapy: Challenges and opportunities","volume":"1","author":"Zhang","year":"2023","journal-title":"Med Adv"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489649","article-title":"Car-T cell therapy for hepatocellular carcinoma: Current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12951-025-03512-w","article-title":"Advancing liver cancer treatment with dual-targeting Car-T therapy","volume":"23","author":"Yang","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ajg.2024.12.002","article-title":"Chimeric antigen receptor-T cells targeting Afp-Gpc3 mediate increased antitumor efficacy in hepatocellular carcinoma","volume":"26","author":"Li","year":"2025","journal-title":"Arab J Gastroenterol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13252","article-title":"Coengineering specificity, safety, and function into T cells for cancer immunotherapy","volume":"320","author":"Giordano Attianese","year":"2023","journal-title":"Immunol Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxab052","article-title":"Engineering strategies for broad application of Tcr-T- and Car-T-cell therapies","volume":"33","author":"Watanabe","year":"2021","journal-title":"Int Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of Hbv-related advanced hepatocellular carcinoma with short-term Hbv-specific Tcr expressed T cells: Results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol Int"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-25-1245","article-title":"Hbv-specific Tcr-T cell therapy combining Mrna electroporation and lentiviral transduction: Treatment regimen for recurrent Hbv-related Hcc after liver transplantation","volume":"31","author":"Zhao","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B73","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00262-025-04038-8","article-title":"Cadonilimab, a Pd-1\/Ctla-4 bispecific antibody in unresectable hepatocellular carcinoma: A real-world study","volume":"74","author":"Wang","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: Advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5501","article-title":"Bispecific Gpc3\/Pd-1 Car-T cells for the treatment of Hcc","volume":"62","author":"Li","year":"2023","journal-title":"Int J Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00766","article-title":"Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results","volume":"10","author":"Mastelic-Gavillet","year":"2019","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202303940","article-title":"Artificial dendritic cells: A new era of promising antitumor immunotherapy","volume":"19","author":"Mateus","year":"2023","journal-title":"Small"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1129483","article-title":"Phase Ii study of the Gpc3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2022.100771","article-title":"Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions","volume":"18","author":"Li","year":"2023","journal-title":"Asian J Pharm Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2911374","article-title":"Oncolytic vesicular stomatitis virus: Optimisation strategies for anti-cancer therapies","volume":"29","author":"Zinovieva","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312009","article-title":"Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer","volume":"67","author":"Samson","year":"2018","journal-title":"Gut"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0289","article-title":"Immunotherapy of hepatocellular carcinoma: Facts and hopes","volume":"24","author":"I\u00f1arrairaegui","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: Why does checkpoint inhibitor immunotherapy not work for all patients","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958720","article-title":"Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184573","article-title":"Immune checkpoints in cancers: From signaling to the clinic","volume":"13","author":"Pisibon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.019","article-title":"Pkc\u03b1\/zfp64\/csf1 axis resets the tumor microenvironment and fuels anti-pd1 resistance in hepatocellular carcinoma","volume":"77","author":"Wei","year":"2022","journal-title":"J Hepatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12607","article-title":"Targeting srsf10 might inhibit m2 macrophage polarization and potentiate anti-pd-1 therapy in hepatocellular carcinoma","volume":"44","author":"Cai","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv0558","article-title":"Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma","volume":"11","author":"Zhang","year":"2025","journal-title":"Sci Adv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-23-0627","article-title":"Blocking cx3cr1+ tumor-associated macrophages enhances the efficacy of anti-pd1 therapy in hepatocellular carcinoma","volume":"12","author":"Xiang","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.02.025","article-title":"Tgf-B1-induced Sox18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating Pd-L1 and Cxcl12","volume":"167","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.08.029","article-title":"Intratumoral stem-like ccr4+ regulatory t cells orchestrate the immunosuppressive microenvironment in hcc associated with hepatitis b","volume":"76","author":"Gao","year":"2022","journal-title":"J Hepatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado3485","article-title":"Riplet promotes lipid metabolism changes associated with cd8 t cell exhaustion and anti-pd-1 resistance in hepatocellular carcinoma","volume":"10","author":"Liang","year":"2025","journal-title":"Sci Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113773","article-title":"Thbs1(+) myeloid cells expand in Sld hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through Trem1","volume":"43","author":"Giraud","year":"2024","journal-title":"Cell Rep"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.024","article-title":"Immunosuppressive Cd10(+)Alpl(+) neutrophils promote resistance to anti-Pd-1 therapy in Hcc by mediating irreversible exhaustion of T cells","volume":"79","author":"Meng","year":"2023","journal-title":"J Hepatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jhep.2024.02.009","article-title":"Crkl dictates anti-Pd-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma","volume":"81","author":"Xie","year":"2024","journal-title":"J Hepatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202507167","article-title":"Plaur(+) neutrophils drive anti-pd-1 therapy resistance in patients with hepatocellular carcinoma by shaping an immunosuppressive microenvironment","volume":"12","author":"Liu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008721","article-title":"Postn(+) cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011648","article-title":"Fmo2(+) cancer-associated fibroblasts sensitize anti-pd-1 therapy in patients with hepatocellular carcinoma","volume":"13","author":"Xu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"Cxcl12(+) tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J Hepatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133308","article-title":"Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001212","article-title":"Lrp4 mutations promote tumor progression and resistance to anti-Pd-1 therapy in recurrent hepatocellular carcinoma","volume":"82","author":"Sun","year":"2025","journal-title":"Hepatology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.95009","article-title":"Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance","volume":"13","author":"Fu","year":"2024","journal-title":"Elife"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1009789","article-title":"Characterization of cancer-related fibroblasts (Caf) in hepatocellular carcinoma and construction of Caf-based risk signature based on single-cell Rna-seq and bulk Rna-seq data","volume":"13","author":"Yu","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-25-2944","article-title":"Targeting tumor-associated macrophages and cancer-associated fibroblasts to overcome therapeutic resistance in hepatocellular carcinoma","volume":"32","author":"Cho","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the Hcc microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J Hepatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011537","article-title":"Multiomics identifies tumor-intrinsic Srebp1 driving immune exclusion in hepatocellular carcinoma","volume":"13","author":"Dadey","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the Ahr restricts a Treg-macrophage suppressive axis induced by L-kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat Commun"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid cell-derived arginase in cancer immune response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-1491","article-title":"L-arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells","volume":"75","author":"Fletcher","year":"2015","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (Mdscs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207746","article-title":"Accumulation of 8-hydroxydeoxyguanosine, L-arginine and glucose metabolites by liver tumor cells are the important characteristic features of metabolic syndrome and non-alcoholic steatohepatitis-associated hepatocarcinogenesis","volume":"21","author":"Kakehashi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1429812","article-title":"Role of tumor-associated macrophages in hepatocellular carcinoma: Impact, mechanism, and therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01231-0","article-title":"Targeting Gsdme-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma","volume":"21","author":"Chen","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03330-2","article-title":"Integrated single-cell and spatial transcriptomic profiling reveals that Cd177(+) Tregs enhance immunosuppression through apoptosis and resistance to immunotherapy in hepatocellular carcinoma","volume":"44","author":"Liang","year":"2025","journal-title":"Oncogene"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115955","article-title":"Fgf19\/Fgfr4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating Igf2bp1-mediated expression of Pd-L1","volume":"170","author":"Guo","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of Mhc class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102329","article-title":"Tumor immune evasion through loss of Mhc class-I antigen presentation","volume":"83","author":"Sari","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of Polycomb silences the Mhc class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"B124","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cac2.12117","article-title":"The Egfr-P38 Mapk axis up-regulates Pd-L1 through Mir-675-5p and down-regulates Hla-Abc via Hexokinase-2 in hepatocellular carcinoma cells","volume":"41","author":"Liu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1688699","article-title":"Overcoming resistance to Pd-1 and Ctla-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-331342","article-title":"Targeting mmp9 in ctnnb1 mutant hepatocellular carcinoma restores cd8(+) t cell-mediated antitumour immunity and improves anti-pd-1 efficacy","volume":"73","author":"Cai","year":"2024","journal-title":"Gut"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328364","article-title":"Targeting ppar-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma","volume":"72","author":"Xiong","year":"2023","journal-title":"Gut"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327133","article-title":"Isoformic pd-1-mediated immunosuppression underlies resistance to pd-1 blockade in hepatocellular carcinoma patients","volume":"72","author":"Tan","year":"2023","journal-title":"Gut"},{"key":"B129","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1038\/s41467-025-60757-7","article-title":"Dual Tigit and Pd-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-Pd-1 therapies: The phase 2 Liverti trial","volume":"16","author":"Hsiehchen","year":"2025","journal-title":"Nat Commun"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v15.i4.617","article-title":"Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy","volume":"15","author":"Feng","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102038","article-title":"Acvr2a attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory t cells in hepatocellular carcinoma","volume":"6","author":"Yasukawa","year":"2025","journal-title":"Cell Rep Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202414909","article-title":"H3k36me3-guided m(6)a modification of oncogenic l1cam-as1 drives macrophage polarization and immunotherapy resistance in hepatocellular carcinoma","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012230","article-title":"Lactylation-driven mvp upregulation boosts immunotherapy resistance by inhibiting pd-l1 degradation in hepatocellular carcinoma","volume":"13","author":"Liu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216935","article-title":"Crispr\/cas9 screen reveals that targeting trim34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma","volume":"593","author":"Yao","year":"2024","journal-title":"Cancer Lett"},{"key":"B135","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12943-025-02480-x","article-title":"Reversal of tumour immune evasion via enhanced mhc-class-i antigen presentation by a dual-functional rna regulated system","volume":"24","author":"Meng","year":"2025","journal-title":"Mol Cancer"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.ccell.2024.10.012","article-title":"Pericancerous cross-presentation to cytotoxic t lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma","volume":"42","author":"Huang","year":"2024","journal-title":"Cancer Cell"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.02.006","article-title":"Targeting hnrnpm inhibits cancer stemness and enhances antitumor immunity in wnt-activated hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.116081","article-title":"Ube2c-Pi3k\/Akt-mediated upregulation of Mthfd2 promotes tumor progression in hepatocellular carcinoma","volume":"170","author":"Tong","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111639","article-title":"Targeting the Pi3k\/Akt\/Mtor pathway in hepatocellular carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"Biomedicines"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218361","article-title":"Targeting Fgfr1-regulated Spp1 signaling repolarizes immunosuppressive macrophages and sensitizes hepatocellular carcinoma to anti-Pd-1 therapy","volume":"646","author":"Jiang","year":"2026","journal-title":"Cancer Lett"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2190-4","article-title":"Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"67","author":"Brown","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2025.2579069","article-title":"Car-T cell therapy for solid tumors: Hif-1\u03b1 as a potential enhancement strategy","volume":"58","author":"Li","year":"2025","journal-title":"Autoimmunity"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.70036","article-title":"Glutaminase-1 mediated glutaminolysis to glutathione synthesis maintains redox homeostasis and modulates ferroptosis sensitivity in cancer cells","volume":"58","author":"Bai","year":"2025","journal-title":"Cell Prolif"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.11.063","article-title":"Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt\/Beta-catenin pathway","volume":"39","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12459","article-title":"Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in Her2-positive gastric cancer","volume":"43","author":"Hu","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70914","article-title":"Gut microbiota and hepatocellular carcinoma: Metabolic products and immunotherapy modulation","volume":"14","author":"Xiao","year":"2025","journal-title":"Cancer Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3639","article-title":"Akkermansia muciniphila might improve anti-Pd-1 therapy against Hcc by changing host bile acid metabolism","volume":"26","author":"Lan","year":"2024","journal-title":"J Gene Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i20.2248","article-title":"Future prospect of \"Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients","volume":"28","author":"Kang","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081427","article-title":"Perspective on the role of gut microbiome in the treatment of hepatocellular carcinoma with immune checkpoint inhibitors","volume":"59","author":"Abenavoli","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1599691","article-title":"Tumor-associated bacteria activate Prdx1-driven glycolysis to promote immune evasion and Pd-1 antibody resistance in hepatocellular carcinoma","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Microbiol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167230","article-title":"Microecological regulation in Hcc therapy: Gut microbiome enhances Ici treatment","volume":"1870","author":"Liu","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.07.015","article-title":"From poo to promise: Fecal microbiota transplants support immunotherapy re-sensitization in solid tumors","volume":"32","author":"Chambers","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321189","article-title":"Study protocol: Fecal microbiota transplant combined with atezolizumab\/bevacizumab in patients with hepatocellular carcinoma who failed to achieve or maintain objective response to atezolizumab\/bevacizumab - the Fab-Hcc pilot study","volume":"20","author":"Pomej","year":"2025","journal-title":"PloS One"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101900","article-title":"Intestinal Akkermansia muciniphila complements the efficacy of Pd1 therapy in Mafld-related hepatocellular carcinoma","volume":"6","author":"Wu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"D'Souza","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322404","article-title":"Tox defines the degree of Cd8+ T cell dysfunction in distinct phases of chronic Hbv infection","volume":"70","author":"Heim","year":"2020","journal-title":"Gut"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1488527","article-title":"Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: Immunotherapy and emerging antiviral strategies","volume":"14","author":"Yu","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i27.3527","article-title":"Immune suppression in chronic hepatitis B infection associated liver disease: A review","volume":"25","author":"Li","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.S307962","article-title":"The mechanisms of Hbv-induced hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2607229","article-title":"Immunotherapy for virus-related hepatocellular carcinoma: Recent progress and future directions","volume":"58","author":"Song","year":"2026","journal-title":"Ann Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101128","article-title":"Hbv-related Hcc development in mice is Stat3 dependent and indicates an oncogenic effect of Hbx","volume":"6","author":"Ringelhan","year":"2024","journal-title":"JHEP Rep"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216048","article-title":"Hcv and Hcc tango-deciphering the intricate dance of disease: A review article","volume":"24","author":"Milosevic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10050991","article-title":"Cd8(+) T cell responses during Hcv infection and Hcc","volume":"10","author":"Hofmann","year":"2021","journal-title":"J Clin Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020533","article-title":"Hepatitis virus and hepatocellular carcinoma: Recent advances","volume":"15","author":"Shen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0145-7","article-title":"From Nash to Hcc: Current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00018-023-04966-7","article-title":"Liver endothelial cells in Nafld and transition to Nash and Hcc","volume":"80","author":"Velliou","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"Nafld-driven Hcc: Safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J Hepatol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1119744","article-title":"Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.2174\/1568009622666220330151725","article-title":"Molecular mechanisms of resistance to tyrosine kinase inhibitors associated with hepatocellular carcinoma","volume":"22","author":"Tian","year":"2022","journal-title":"Curr Cancer Drug Targets"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.765101","article-title":"Immunotherapy for hepatocellular carcinoma: Current status and future prospects","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002191","article-title":"Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: Cohort a report in a multicenter phase Ib\/Ii trial","volume":"9","author":"Mei","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B177","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12876-024-03144-8","article-title":"Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: A systematic review and single-arm meta-analysis","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.09.051","article-title":"Targeted and immune-based therapies for hepatocellular carcinoma","volume":"156","author":"Greten","year":"2019","journal-title":"Gastroenterology"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2022.08.003","article-title":"Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma","volume":"21","author":"Zhu","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B181","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (Cosmic-312): A multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188762","article-title":"Tumor-associated neutrophils and neutrophil-targeted cancer therapies","volume":"1877","author":"Que","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668731","article-title":"Cancer-associated fibroblasts and tumor-associated macrophages in cancer and cancer immunotherapy","volume":"11","author":"Raskov","year":"2021","journal-title":"Front Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1592259","article-title":"Harnessing multi-omics and artificial intelligence: Revolutionizing prognosis and treatment in hepatocellular carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092622","article-title":"Epigenetic associations between lncrna\/circrna and mirna in hepatocellular carcinoma","volume":"12","author":"Han","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113019","article-title":"Linc00963: A potential cancer diagnostic and therapeutic target","volume":"150","author":"Xie","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201803_14574","article-title":"Linc00963 promotes hepatocellular carcinoma progression by activating pi3k\/akt pathway","volume":"22","author":"Wu","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10415","article-title":"Downregulating serine hydroxymethyltransferase 2 (shmt2) suppresses tumorigenesis in human hepatocellular carcinoma","volume":"7","author":"Woo","year":"2016","journal-title":"Oncotarget"},{"key":"B189","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/s41467-024-49087-2","article-title":"Fbxo7 ubiquitinates prmt1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma","volume":"15","author":"Luo","year":"2024","journal-title":"Nat Commun"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41467-023-36708-5","article-title":"Phgdh arginine methylation by prmt1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113305","article-title":"Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance","volume":"153","author":"Rahman","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B192","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B193","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J Nanobiotechnology"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202005236","article-title":"Nanotechnology for hepatocellular carcinoma: From surveillance, diagnosis to management","volume":"17","author":"Wu","year":"2021","journal-title":"Small"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1039\/d2ra05127c","article-title":"Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment","volume":"12","author":"ia","year":"2022","journal-title":"RSC Adv"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.07.001","article-title":"Organoid models of human liver cancers derived from tumor needle biopsies","volume":"24","author":"Nuciforo","year":"2018","journal-title":"Cell Rep"},{"key":"B197","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13577-024-01148-w","article-title":"Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma","volume":"38","author":"Gao","year":"2024","journal-title":"Hum Cell"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1536854","article-title":"Organoids and spheroids: Advanced in vitro models for liver cancer research","volume":"12","author":"Pastore","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1180184","article-title":"Liver organoids: A promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12272-022-01390-6","article-title":"Advances in liver organoids: Model systems for liver disease","volume":"45","author":"Lee","year":"2022","journal-title":"Arch Pharm Res"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302640","article-title":"Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of hcc patients","volume":"10","author":"Zou","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1105454","article-title":"Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.iliver.2025.100179","article-title":"The application of liver cancer organoids in tumour precision medicine: A comprehensive review","volume":"4","author":"Mo","year":"2025","journal-title":"Iliver"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.770465","article-title":"Organoid models for precision cancer immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41420-025-02505-w","article-title":"Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: A cutting-edge tool for advancing personalised treatments","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov"},{"key":"B206","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.actbio.2021.03.002","article-title":"Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling","volume":"132","author":"Kim","year":"2021","journal-title":"Acta Biomater"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.3390\/mi14081648","article-title":"Application of 3d bioprinting in liver diseases","volume":"14","author":"Li","year":"2023","journal-title":"Micromachines (Basel)"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: From pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104997","article-title":"Liver microenvironment and therapy resistance in hepatocellular carcinoma","volume":"216","author":"Rahi","year":"2025","journal-title":"Crit Rev Oncology\/Hematology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1808109\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:41:46Z","timestamp":1776231706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1808109\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":209,"alternative-id":["10.3389\/fimmu.2026.1808109"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1808109","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1808109"}}